These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21981752)

  • 1. Using absorption simulation and gastric pH modulated dog model for formulation development to overcome achlorhydria effect.
    Mitra A; Kesisoglou F; Beauchamp M; Zhu W; Chiti F; Wu Y
    Mol Pharm; 2011 Dec; 8(6):2216-23. PubMed ID: 21981752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product development.
    Mitra A; Kesisoglou F
    Mol Pharm; 2013 Nov; 10(11):3970-9. PubMed ID: 23844623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
    Good DJ; Hartley R; Mathias N; Crison J; Tirucherai G; Timmins P; Hussain M; Haddadin R; Koo O; Nikfar F; Fung NK
    Mol Pharm; 2015 Dec; 12(12):4434-44. PubMed ID: 26536519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
    Pang J; Dalziel G; Dean B; Ware JA; Salphati L
    Mol Pharm; 2013 Nov; 10(11):4024-31. PubMed ID: 23980865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pH dependent absorption using in vitro, in silico, and in vivo rat models: Early liability assessment during lead optimization.
    Saxena A; Shah D; Padmanabhan S; Gautam SS; Chowan GS; Mandlekar S; Desikan S
    Eur J Pharm Sci; 2015 Aug; 76():173-80. PubMed ID: 25960252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy.
    Gesenberg C; Mathias NR; Xu Y; Crison J; Savant I; Saari A; Good DJ; Hemenway JN; Narang AS; Schartman RR; Zheng N; Buzescu A; Patel J
    Pharm Res; 2019 Oct; 36(12):164. PubMed ID: 31637544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria.
    Kou D; Dwaraknath S; Fischer Y; Nguyen D; Kim M; Yiu H; Patel P; Ng T; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2017 Oct; 14(10):3577-3587. PubMed ID: 28834434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers.
    Adachi M; Hinatsu Y; Kusamori K; Katsumi H; Sakane T; Nakatani M; Wada K; Yamamoto A
    Eur J Pharm Sci; 2015 Aug; 76():225-30. PubMed ID: 25988287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389.
    Badawy SI; Gray DB; Zhao F; Sun D; Schuster AE; Hussain MA
    Pharm Res; 2006 May; 23(5):989-96. PubMed ID: 16715389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a canine model to enable the preclinical assessment of pH-dependent absorption of test compounds.
    Fancher RM; Zhang H; Sleczka B; Derbin G; Rockar R; Marathe P
    J Pharm Sci; 2011 Jul; 100(7):2979-88. PubMed ID: 21254068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
    Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.
    Kuminek G; Salehi N; Waltz NM; Sperry DC; Greenwood DE; Hate SS; Amidon GE
    Mol Pharm; 2023 Jan; 20(1):147-158. PubMed ID: 36367432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
    Wu Y; Loper A; Landis E; Hettrick L; Novak L; Lynn K; Chen C; Thompson K; Higgins R; Batra U; Shelukar S; Kwei G; Storey D
    Int J Pharm; 2004 Nov; 285(1-2):135-46. PubMed ID: 15488686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model.
    Zhou R; Moench P; Heran C; Lu X; Mathias N; Faria TN; Wall DA; Hussain MA; Smith RL; Sun D
    Pharm Res; 2005 Feb; 22(2):188-92. PubMed ID: 15783065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
    Shono Y; Jantratid E; Dressman JB
    Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the rat model for preclinical evaluation of pH-dependent oral absorption in humans.
    Lubach JW; Chen JZ; Hau J; Imperio J; Coraggio M; Liu L; Wong H
    Mol Pharm; 2013 Nov; 10(11):3997-4004. PubMed ID: 23961831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
    Heigoldt U; Sommer F; Daniels R; Wagner KG
    Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.